Abstract CT165: A Phase 1/2a, Multicenter, Open-Label, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 (a B7-H3-targeting ADC) in Patients with Advanced/metastatic Solid Tumors